Aller au contenu principal
Fermer
  2. Aide
  2. Aide

Transgene presents e-poster outlining detailed results from the Phase 1b/2 trial of TG4001 in combination with avelumab in advanced HPV-positive cancers at SITC 2020
information fournie par Boursorama CP 09/11/2020 à 17:45

Ajouter Boursorama à vos sources

­ - Combination of TG4001 and avelumab demonstrated a clinically relevant anti-tumor activity with an overall response rate (ORR) of 23.5%
­ - Presence of liver metastases had a notable impact on outcomes: in patients without liver metastases, an ORR of 34.8% and a median progression-free survival (PFS) of 5.6 months were achieved
­ - Treatment associated with changes in the tumor microenvironment characterized by a significant and sustainable immune response and activity against the tumor

Conference call to take place on November 12, at 6:00 p.m. CET (in English).

.../...

Valeurs associées

TRANSGENE
0,7300 EUR Euronext Paris +4,29%

0 commentaire

Signaler le commentaire

Fermer

A lire aussi

Mes listes

valeur

dernier

var.
CAC 40
7 814,51 -1,05%
Pétrole Brent
102,64 -0,35%
SCHNEIDER ELECTRIC
274,8 -9,31%
HAFFNER ENERGY
0,726 -0,27%
DBT
0,0874 +6,59%
Chargement...

Pages les plus populaires

L'offre BoursoBank